Screener
Halozyme Therapeutics HALO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's restricted cash?
- Halozyme Therapeutics (HALO) reported restricted cash of $848K in Q2 2026.
- What is the long-term trend for Halozyme Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's restricted cash has grown at a 39.1% compound annual growth rate (CAGR), from $500K to $2.6M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Halozyme Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude